Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
June 30, 2022 09:15 ET | Cyclacel
- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
June 22, 2022 07:04 ET | Cyclacel
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 16:05 ET | Cyclacel
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 -          - First Patients Dosed in Phase 1/2 Study of...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results
May 04, 2022 09:15 ET | Cyclacel
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
April 19, 2022 09:15 ET | Cyclacel
BERKELEY HEIGHTS, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
April 12, 2022 07:00 ET | Cyclacel
-New Preclinical Data Highlight Fadraciclib’s Apoptosis Enabling Mechanism in Leukemia- -Remarkable Synergy Observed with Venetoclax, esp. in Resistant CLL cells with 17p Deletion- BERKELEY HEIGHTS,...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022 16:05 ET | Cyclacel
-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –          -Cash Runway to Mid 2023-          -Conference Call Scheduled for March 28, 2022, at...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results
March 22, 2022 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 09, 2022 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference
February 07, 2022 07:00 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...